208 related articles for article (PubMed ID: 38703383)
1. Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics.
Park H; Kim M; Kim HL; Cho S; Yoon EL; Jun DW
Hepatol Res; 2024 May; ():. PubMed ID: 38703383
[TBL] [Abstract][Full Text] [Related]
2. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
3. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
Hepatol Res; 2024 Jan; ():. PubMed ID: 38234088
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.
Park H; Yoon EL; Ito T; Jo AJ; Kim M; Lee J; Kim HL; Arai T; Atsukawa M; Kawanaka M; Toyoda H; Ishigami M; Yu ML; Jun DW; Nguyen MH
JAMA Netw Open; 2023 Aug; 6(8):e2329568. PubMed ID: 37589973
[TBL] [Abstract][Full Text] [Related]
5. Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients.
Dabbah S; Ben Yakov G; Kaufmann MI; Cohen-Ezra O; Likhter M; Davidov Y; Ben Ari Z
Minerva Gastroenterol (Torino); 2023 Oct; ():. PubMed ID: 37889111
[TBL] [Abstract][Full Text] [Related]
6. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
7. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
8. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
Kobayashi N; Tada T; Nishimura T; Matono T; Yuri Y; Takashima T; Aizawa N; Ikeda N; Fukunishi S; Hashimoto M; Ohyanagi M; Enomoto H; Iijima H
Hepatol Res; 2024 May; 54(5):429-438. PubMed ID: 38015179
[TBL] [Abstract][Full Text] [Related]
10. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
11. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
Eur Radiol; 2023 Nov; ():. PubMed ID: 37987833
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting.
Park H; Yoon EL; Kim M; Lee J; Kim HL; Cho S; Nah EH; Jun DW
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37738414
[TBL] [Abstract][Full Text] [Related]
15. Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease.
Nouso K; Kawanaka M; Fujii H; Kariyama K; Toyoda H; Iwaki M; Hayashi H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Kumada T; Okanoue T;
Hepatol Res; 2024 Apr; ():. PubMed ID: 38661715
[TBL] [Abstract][Full Text] [Related]
16. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38695344
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Kang MK; Kim MC
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837575
[No Abstract] [Full Text] [Related]
18. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
[TBL] [Abstract][Full Text] [Related]
19. A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease.
Mathew JF; Panackel C; Jacob M; Ramesh G; John N
J Clin Exp Hepatol; 2024; 14(5):101407. PubMed ID: 38699513
[TBL] [Abstract][Full Text] [Related]
20. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
